Sensus Healthcare (SRTS) Investor Presentation summary

Market opportunity and industry context

• 1 in 5 Americans will develop skin cancer in their lifetime, highlighting a significant healthcare need.

• Large U.S. market for superficial radiation therapy (SRT) with international and pipeline expansion opportunities.

• Worldwide installed base of approximately 750 systems, indicating broad adoption.

Technology and product portfolio

• SRT-100+ and SRT-100 Vision systems use low-energy photon radiotherapy, focusing energy on the skin surface with proprietary applicators.

• SRT-100 Vision offers image-guided therapy, disease tracking, and ultrasound capabilities, enabling “see & treat” approaches.

• Sentinel cloud platform provides asset management, HIPAA-compliant patient data, and remote diagnostics.

• TransDermal Infusion system enables needle-free delivery of aesthetic medicines, with FDA clearances expected for new products.

• SensusLASER and smart lasers feature two-way communication and cloud-based data storage.

Clinical applications and outcomes

• SRT is FDA-cleared for non-melanoma skin cancer and keloid treatment, offering superior cosmetic outcomes and no scarring.

• SRT is the only FDA-cleared system for keloids, with insurance coverage when combined with SRT.

• Clinical studies show high cure and success rates: 98.9% for skin cancer (5-year), 97% for keloids post-surgery.

• SRT is being studied for additional indications, including COVID-19 pneumonia and animal cancer.